Astellas Pharma Inc. (ALPMY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Astellas Pharma Inc. (ALPMY) Healthcare & Pipeline Overview

Astellas Pharma Inc. is a leading global pharmaceutical company focused on delivering innovative therapies across multiple therapeutic areas, including oncology and urology, with a commitment to improving patient outcomes through research and development.

What Is the Investment Thesis for ALPMY?

Astellas Pharma Inc. is positioned for growth driven by its strong product pipeline and strategic collaborations. The company's P/E ratio of 11.00 suggests it is valued competitively within the industry, while a gross margin of 76.1% indicates operational efficiency. Key growth catalysts include the expansion of its oncology portfolio, particularly with XTANDI and XOSPATA, which have significant market potential. Additionally, Astellas' focus on chronic conditions, such as kidney disease and urology, aligns with growing healthcare demands, providing a solid foundation for revenue growth. The company's ongoing collaborations with leading research institutions and biotech firms further enhance its innovation capabilities, potentially leading to new product launches and market share expansion.

Based on FMP financials and quantitative analysis

ALPMY Key Highlights

Market Cap of $26.1B indicates a substantial presence in the pharmaceutical sector.

• P/E ratio of 11.00 reflects competitive valuation compared to industry peers.
• Profit margin of 13.6% showcases effective cost management and operational efficiency.
• Gross margin of 76.1% exceeds industry averages, highlighting strong product pricing power.
• Dividend yield of 3.62% provides a steady income stream for investors.

Who Are ALPMY's Competitors?

ALPMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ALPMY's Key Strengths?

Strong product pipeline with innovative therapies.

• High gross margin indicating operational efficiency.
• Established global presence and distribution network.
• Robust R&D capabilities through strategic collaborations.

What Are ALPMY's Weaknesses?

Dependence on a few key products for revenue.

• Exposure to patent expiration risks.
• Limited market presence in certain therapeutic areas.
• Potential challenges in regulatory approvals.

What Could Drive ALPMY Stock Higher?

ALPMY catalyst: Expansion of the oncology product line with new therapies expected to launch in the next 12-18 months.

• Strategic collaborations with biotech firms enhancing R&D capabilities and product development.
• Continued growth in the chronic kidney disease treatment market driven by increasing patient awareness.
• Potential new drug approvals in the pipeline that could significantly impact revenue streams.
• Investment in innovative technologies and research to develop next-generation therapies.

What Are the Key Risks for ALPMY?

Exposure to patent expiration risks affecting key revenue-generating products.

• Intense competition from both established pharmaceutical companies and emerging biotech firms.
• Regulatory challenges that could delay product approvals and market entry.
• Pricing pressures from healthcare reforms and cost containment measures impacting profitability.
• Market volatility affecting stock performance and investor sentiment.

What Are the Growth Opportunities for ALPMY?

• Oncology Expansion: Astellas is focusing on expanding its oncology portfolio, particularly with XTANDI and XOSPATA, which cater to significant unmet medical needs.
• Chronic Kidney Disease Treatments: The introduction of Evrenzo for anemia associated with chronic kidney disease positions Astellas to tap into a growing patient population. The chronic kidney disease market is projected to grow to $20 billion by 2027, driven by rising prevalence and awareness, offering Astellas a lucrative opportunity.
• Urology Market Growth: Astellas' products like Betanis/Myrbetriq/BETMIGA and Vesicare address overactive bladder conditions, a market expected to grow significantly due to increasing aging populations. This market is projected to reach $5 billion by 2026, providing Astellas with a chance to strengthen its market share.
• Strategic Collaborations: Astellas' partnerships with biotech firms and research institutions enhance its R&D capabilities, potentially leading to innovative therapies. Collaborations like those with Merck & Co., Inc. and Harvard University can accelerate product development timelines and improve competitive positioning.
• Cell Therapy Programs: The strategic collaboration with Minovia Therapeutics Ltd. for cell therapy programs targeting mitochondrial dysfunction presents a unique growth avenue. The cell therapy market is anticipated to grow to $25 billion by 2030, allowing Astellas to diversify its product portfolio and capture emerging opportunities.

What Are ALPMY's Competitive Advantages?

• Strong patent portfolio protecting key products from generic competition.
• Established brand recognition and trust in the pharmaceutical industry.
• Robust R&D capabilities supported by strategic collaborations.
• Diverse product portfolio addressing multiple therapeutic areas.
• Global presence allowing for market penetration and scalability.

What Does ALPMY Do?

Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. The company engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Over the years, Astellas has evolved through strategic mergers and acquisitions, including the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., which formed Astellas in 2005. The company has developed a robust portfolio of products, including XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia; and PADCEV, a treatment for metastatic urothelial cancer. Other key products include Betanis/Myrbetriq/BETMIGA for overactive bladder, Evrenzo for anemia related to chronic kidney disease, and immunosuppressants like Prograf and Advagraf. Astellas also invests in research collaborations and strategic alliances, such as its partnership with Harvard University for the development of therapeutics and technologies. With approximately 14,754 employees, Astellas operates in numerous countries and continues to focus on expanding its therapeutic offerings and enhancing patient care through innovative solutions.

What Products and Services Does ALPMY Offer?

• Manufacture and market a wide range of pharmaceuticals globally.
• Develop innovative therapies for oncology, urology, and transplant medicine.
• Engage in strategic collaborations with research institutions and biotech companies.
• Conduct clinical trials to evaluate new drug candidates.
• Provide treatments for chronic conditions such as kidney disease and overactive bladder.
• Focus on patient-centric solutions to enhance healthcare outcomes.

How Does ALPMY Make Money?

• Generate revenue through the sale of prescription medications and therapies.
• Engage in partnerships and collaborations to enhance R&D capabilities.
• Invest in innovative drug development to address unmet medical needs.
• Leverage strong intellectual property to protect and monetize product offerings.
• Utilize a global distribution network to reach diverse markets.

What Industry Does ALPMY Operate In?

The pharmaceutical industry is experiencing robust growth, driven by increasing healthcare demands and advancements in drug development technologies. Astellas Pharma Inc. operates in a competitive landscape, facing rivals such as Otsuka Holdings Co., Ltd. (OTSKF), Orion Oyj (ORINY), and Genmab A/S (GNMSF). Astellas' focus on innovative therapies positions it well to capitalize on these trends and maintain a competitive edge in the sector.

Who Are ALPMY's Key Customers?

• Healthcare providers including hospitals and clinics.
• Patients requiring medications for chronic and acute conditions.
• Pharmaceutical distributors and wholesalers.
• Research institutions and academic partners.
• Regulatory bodies for drug approval and compliance.

Astellas Pharma Inc. Financial Trajectory

Astellas Pharma Inc. (ALPMY) reported $4.23B in revenue for Q1 FY2027, reflecting 0.3% growth compared to the prior quarter. The company recorded net income of $934.1M, with diluted EPS of $0.52. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, ALPMY averaged $0.35 in diluted EPS.

Company Profile

Astellas Pharma Inc. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Naoki Okamura. ALPMY has traded publicly since 2009.

How Astellas Pharma Inc. Is Valued

Astellas Pharma Inc. carries a market capitalization of $26.1B, placing it in the large-cap category. Relative to its peer group, ALPMY's quantitative score of 55/100 is roughly in line with the peer average of 56/100.

Return on equity for Astellas Pharma Inc. stands at 17.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.2%, showing how much profit it generates from its asset base. ALPMY trades at a trailing price-to-earnings ratio of 11.00, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 12.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.1%, the inverse of the P/E and a quick read on earnings relative to price.

Astellas Pharma Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.95 places it in the grey zone, a middle ground that warrants monitoring.

Astellas Pharma Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 46.4% above estimates on average.

ALPMY Financials

ALPMY Latest News

ALPMY Analyst Consensus

ALPMY MoonshotScore

What Investors Ask About Astellas Pharma Inc. (ALPMY) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources